Bisphosphonates and atypical femoral fractures: A time for reflection

Maturitas

Volumn 65, Issue 1, 2010, Pages 3-4

  Compston, J E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; ZOLEDRONIC ACID;

BONE REMODELING; BONE SCINTISCANNING; CLINICAL PRACTICE; COMORBIDITY; DRUG MEGADOSE; EDITORIAL; FEMUR FRACTURE; HORMONE SUBSTITUTION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; X RAY;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 72149096516     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.11.002     Document Type: Editorial

References (5)

1. Odvina C.V., Zerwekh J.E., Rao S., Maalouf N., Gottschalk F.A., and Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
2. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., and Lorich D.G. Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22 (2008) 346-350
3. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporosis Int 20 (2009) 1353-1362
4. Abrahamsen B., Eiken P., and Eastell R.E. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24 (2009) 1095-1102
5. Wernecke G., Namduri S., DiCarlo E.F., Schneider R., and Lane J. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J 4 (2008) 123-127